DE602004017477D1 - Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential - Google Patents
Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem ZetapotentialInfo
- Publication number
- DE602004017477D1 DE602004017477D1 DE602004017477T DE602004017477T DE602004017477D1 DE 602004017477 D1 DE602004017477 D1 DE 602004017477D1 DE 602004017477 T DE602004017477 T DE 602004017477T DE 602004017477 T DE602004017477 T DE 602004017477T DE 602004017477 D1 DE602004017477 D1 DE 602004017477D1
- Authority
- DE
- Germany
- Prior art keywords
- oil
- water emulsion
- cationic agent
- low concentration
- zeta potential
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Colloid Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04292645A EP1655021B1 (de) | 2004-11-09 | 2004-11-09 | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004017477D1 true DE602004017477D1 (de) | 2008-12-11 |
Family
ID=34931510
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004017477T Active DE602004017477D1 (de) | 2004-11-09 | 2004-11-09 | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
DE602005010733T Active DE602005010733D1 (de) | 2004-11-09 | 2005-10-10 | Ophthalmische emulsion mit einem immunosuppressiven mittel |
DE602005026464T Active DE602005026464D1 (de) | 2004-11-09 | 2005-10-10 | Ophthalmische Emulsionen mit einem immunsuppressiven Mittel |
DE602005012136T Active DE602005012136D1 (de) | 2004-11-09 | 2005-10-10 | Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential |
DE602005011480T Active DE602005011480D1 (de) | 2004-11-09 | 2005-10-10 | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005010733T Active DE602005010733D1 (de) | 2004-11-09 | 2005-10-10 | Ophthalmische emulsion mit einem immunosuppressiven mittel |
DE602005026464T Active DE602005026464D1 (de) | 2004-11-09 | 2005-10-10 | Ophthalmische Emulsionen mit einem immunsuppressiven Mittel |
DE602005012136T Active DE602005012136D1 (de) | 2004-11-09 | 2005-10-10 | Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential |
DE602005011480T Active DE602005011480D1 (de) | 2004-11-09 | 2005-10-10 | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
Country Status (14)
Country | Link |
---|---|
US (5) | US8298568B2 (de) |
EP (1) | EP1655021B1 (de) |
JP (3) | JP5587936B2 (de) |
CN (3) | CN101014317A (de) |
AT (5) | ATE412400T1 (de) |
DE (5) | DE602004017477D1 (de) |
DK (1) | DK1809237T3 (de) |
ES (4) | ES2314354T3 (de) |
HK (2) | HK1107938A1 (de) |
IL (3) | IL181446A (de) |
MX (2) | MX2007003045A (de) |
NZ (1) | NZ554929A (de) |
PT (2) | PT1809237E (de) |
ZA (1) | ZA200703751B (de) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US8236335B2 (en) | 1999-04-28 | 2012-08-07 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
ES2314354T3 (es) * | 2004-11-09 | 2009-03-16 | Novagali Pharma S.A. | Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo. |
EP1871349A1 (de) * | 2005-04-11 | 2008-01-02 | Nanobio Corporation | Quartäre ammoniumhalogenide zur behandlung von infektionskrankheiten |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
CA2618974C (en) * | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
US7797337B2 (en) * | 2005-09-29 | 2010-09-14 | Scenera Technologies, Llc | Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
CA2645080A1 (en) * | 2006-03-07 | 2007-09-13 | Novavax,Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
WO2007111806A2 (en) * | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
WO2008035246A2 (en) | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
AU2014201978B2 (en) * | 2006-07-28 | 2016-03-10 | Santen Sas | Compositions containing quaternary ammonium compounds |
US20080026013A1 (en) * | 2006-07-28 | 2008-01-31 | Laura Rabinovich-Guilatt | Compositions containing quaternary ammonium compounds |
US9132071B2 (en) * | 2006-07-28 | 2015-09-15 | Santen Sas | Compositions containing quaternary ammonium compounds |
ES2428868T3 (es) * | 2006-07-28 | 2013-11-12 | Novagali Pharma S.A. | Composiciones que contienen compuestos de amonio cuaternario |
EP2444829A1 (de) | 2006-09-14 | 2012-04-25 | Carl Zeiss SMT GmbH | Optische Elementeinheit und Verfahren zum Stützen eines optischen Elements |
EP1938801A1 (de) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
EP1985298A1 (de) | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge |
US8747872B2 (en) | 2007-05-02 | 2014-06-10 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US20090018057A1 (en) * | 2007-07-09 | 2009-01-15 | Gregory Lambert | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES |
US8512687B2 (en) * | 2007-07-09 | 2013-08-20 | Novagali Pharma Sa | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
AU2008344909B2 (en) * | 2007-10-16 | 2013-06-06 | Sun Pharma Advanced Research Company Limited | Ophthalmic composition comprising a prostaglandin |
US7834172B2 (en) * | 2007-11-14 | 2010-11-16 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC |
WO2009063081A2 (en) * | 2007-11-14 | 2009-05-22 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. |
EP2077104A1 (de) * | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Mizellare Zusammensetzungen mit ophtalmischen Anwendungen |
EP2077105A1 (de) * | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität |
EP2127638A1 (de) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom |
RU2504380C2 (ru) * | 2008-09-04 | 2014-01-20 | Сантен Фармасьютикал Ко., Лтд. | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α |
PL2331128T3 (pl) * | 2008-09-05 | 2014-06-30 | Ceva Sante Animale Sa | Kompozycja zawierająca chitozan do doocznego podawania szczepionki (szczepionek) ptakom |
EP2376089B1 (de) | 2008-11-17 | 2018-03-14 | The Regents of the University of Michigan | Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür |
CA2750242C (en) | 2009-02-12 | 2018-05-22 | Incept, Llc | Drug delivery through hydrogel plugs |
EP2228058A1 (de) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür |
EP2228057A1 (de) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
EP2498784A2 (de) * | 2009-11-09 | 2012-09-19 | Allergan, Inc. | Zusammensetzungen zur förderung des haarwuchses |
EP2389939A1 (de) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen |
CN103124541B (zh) * | 2010-07-15 | 2015-09-30 | 艾诺维亚股份有限公司 | 眼药物递送 |
US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
CA2866067C (en) | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
MY175318A (en) | 2011-01-26 | 2020-06-19 | Allergan Inc | Androgen composition for treating an opthalmic condition |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
EP3701939A1 (de) | 2011-11-15 | 2020-09-02 | Allergan, Inc. | Suspensionen von cyclosporin-a der form 2 |
AU2012339701B8 (en) | 2011-11-15 | 2017-11-16 | Allergan, Inc. | Autoclavable suspensions of cyclosporin A Form 2 |
AU2012347926B2 (en) | 2011-12-05 | 2018-03-15 | Incept, Llc | Medical organogel processes and compositions |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
WO2013125026A1 (ja) * | 2012-02-24 | 2013-08-29 | ファインバイオメディカル有限会社 | 潤滑性調整液 |
CA3050298A1 (en) * | 2012-08-24 | 2014-02-27 | Sun Pharma Global Fze | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions |
EP2892564A4 (de) * | 2012-09-06 | 2016-04-27 | Univ Nanyang Tech | Arzneistoffabgabesysteme auf basis von hyaluronsäure |
CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
ES2797376T3 (es) | 2013-01-24 | 2020-12-02 | Palvella Therapeutics Inc | Composiciones para la administración transdérmica de inhibidores de mTOR |
WO2014138085A1 (en) | 2013-03-05 | 2014-09-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery |
CN105073112B (zh) * | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
US20140275261A1 (en) * | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
RU2513597C1 (ru) * | 2013-04-17 | 2014-04-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения воспалительных состояний переднего отрезка глаза |
NO2753788T3 (de) | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
EP3013790A1 (de) | 2013-06-27 | 2016-05-04 | Mylan Laboratories Ltd. | Verfahren zur herstellung von nepafenac |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
JP2017505349A (ja) | 2014-02-11 | 2017-02-16 | ドクター レディズ ラボラトリーズ リミテッド | セレコキシブの非経口組成物 |
CA2939660A1 (en) * | 2014-02-14 | 2015-08-20 | Jingjun Huang | Compositions of nanoemulsion delivery systems |
WO2015189387A1 (en) * | 2014-06-13 | 2015-12-17 | Sanofi | Nanocapsular formulation of active pharmaceutical ingredients |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
EP3233174B1 (de) * | 2014-12-19 | 2021-03-31 | Kemin Industries, Inc. | Intraokulare abgabe bioaktiver moleküle mittels iontophorese |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
JP6993231B2 (ja) * | 2015-02-06 | 2022-02-04 | アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー | 高分子で安定化された医薬製剤用水中油型エマルジョンの調製 |
CN106176600A (zh) * | 2015-05-07 | 2016-12-07 | 上海现代药物制剂工程研究中心有限公司 | 一种前列地尔冻干微乳剂、原料组合物及其制备方法 |
WO2016182926A1 (en) * | 2015-05-08 | 2016-11-17 | Affinsci Inc. | Preparation of nanoemulsions |
US20190231885A1 (en) | 2015-11-10 | 2019-08-01 | Sun Pharma Global Fze | Topical formulations and uses thereof |
CN109843316A (zh) | 2016-02-29 | 2019-06-04 | 太阳制药全球公司 | 含有环孢菌素的局部制剂及其用途 |
JP6906899B2 (ja) * | 2016-03-30 | 2021-07-21 | 小林製薬株式会社 | 乳化組成物 |
EP3452152A4 (de) | 2016-05-03 | 2020-01-01 | Pneuma Respiratory, Inc. | Verfahren zur erzeugung und abgabe von tröpfchen an das lungensystem unter verwendung einer tröpfchenabgabevorrichtung |
US11285274B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device |
WO2017192773A1 (en) | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency |
WO2017192767A1 (en) | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system and methods of use |
WO2017192782A1 (en) | 2016-05-03 | 2017-11-09 | Pneuma Respiratory, Inc. | Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment |
US11395853B2 (en) | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
PT3266446T (pt) * | 2016-07-07 | 2019-01-30 | Salvat Lab Sa | Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média |
CN106782348A (zh) * | 2017-01-04 | 2017-05-31 | 深圳市华星光电技术有限公司 | 一种led背光驱动电路及液晶显示器 |
JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物およびその使用方法 |
EP3634552A4 (de) | 2017-05-19 | 2021-03-03 | Pneuma Respiratory, Inc. | Vorrichtung zur ausgabe von trockenpulver und verfahren zur verwendung |
KR20200069261A (ko) * | 2017-05-30 | 2020-06-16 | 엑시모어 엘티디. | 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법 |
JP7227163B2 (ja) | 2017-06-10 | 2023-02-21 | アイノビア,インコーポレイティド | 流体を取扱い、目に流体を送出するための方法および装置 |
EP3691728B1 (de) | 2017-10-04 | 2024-05-22 | Pneuma Respiratory, Inc. | Elektronische atembetätigte inline-tröpfchenabgabevorrichtung |
WO2019079461A1 (en) | 2017-10-17 | 2019-04-25 | Pneuma Respiratory, Inc. | NASAL MEDICATION DELIVERY APPARATUS AND METHODS OF USE |
WO2019089573A1 (en) | 2017-10-30 | 2019-05-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor |
CA3082192A1 (en) | 2017-11-08 | 2019-05-16 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
JP7416430B2 (ja) * | 2018-02-26 | 2024-01-17 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッド | 薬物送達システム |
JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物および使用方法 |
CN109010268B (zh) * | 2018-09-28 | 2020-07-10 | 湖北远大天天明制药有限公司 | 一种提高氯霉素稳定性的眼用组合物及其制备方法 |
US20210290562A1 (en) | 2018-12-11 | 2021-09-23 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
CN110237233B (zh) * | 2019-07-30 | 2021-01-15 | 沈阳兴齐眼药股份有限公司 | 一种含有环孢素的眼用药物组合物、其制备方法及用途 |
EP4069220A4 (de) * | 2019-12-04 | 2024-04-24 | Restore Vision, LLC. | Ophthalmische formulierungen zur behandlung von presbyopie |
US20230210771A1 (en) * | 2020-06-10 | 2023-07-06 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
KR20240037245A (ko) | 2021-06-22 | 2024-03-21 | 뉴마 레스퍼러토리 인코포레이티드 | 푸시 이젝션에 의한 액적 전달 장치 |
CN113577024B (zh) * | 2021-08-20 | 2023-05-05 | 山西利普达医药科技有限公司 | 一种眼用组合物及其制备方法和应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
JPH0818989B2 (ja) | 1984-01-12 | 1996-02-28 | 株式会社ミドリ十字 | 脂肪乳剤中のプロスタグランジンの安定化方法 |
US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
JP2602964B2 (ja) | 1989-10-16 | 1997-04-23 | 裕 水島 | プロスタグランジン類縁体およびその脂肪乳剤 |
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
EP0656779B1 (de) * | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge |
IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
JP3551977B2 (ja) * | 1993-04-08 | 2004-08-11 | ライオン株式会社 | 安定なビタミンa類及びビタミンe類可溶化点眼剤 |
ATE168553T1 (de) * | 1993-06-25 | 1998-08-15 | Alcon Cusi S A | Neue verwendung von polymeren membranen zum ausgeben von pharmazeutischen lösungen, die quarternäre, als konserviermittel dienende ammoniumverbindungen enthalten und entsprechender dosierbehälter |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
US5739105A (en) * | 1994-06-01 | 1998-04-14 | Yuhan Corporation | Cyclosporin containing composition and process for the preparation thereof |
ES2094688B1 (es) * | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US6011062A (en) | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US5767153A (en) * | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
EP0878197B1 (de) | 1997-05-14 | 2002-08-21 | Senju Pharmaceutical Co., Ltd. | Difluprednat enthaltende Zusammensetzungen |
JP3410364B2 (ja) * | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
WO2000038663A2 (en) * | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
US20020136771A1 (en) * | 1998-12-31 | 2002-09-26 | Amitee Cosmetics, Inc. | Stabilized ascorbic acid composition |
FR2823441B1 (fr) * | 2001-04-12 | 2004-09-10 | Thea Lab | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation |
CA2443937A1 (en) * | 2001-04-23 | 2002-10-31 | Randall D. Glickman | Prostanoids augment ocular drug penetration |
EP1528937B1 (de) * | 2001-06-05 | 2016-08-10 | The Regents Of The University Of Michigan | Nanoemulsionsvakzine |
US6872705B2 (en) * | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
WO2003053405A1 (en) * | 2001-11-01 | 2003-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and composition for dry eye treatment |
US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
KR100446960B1 (ko) | 2001-12-04 | 2004-09-01 | 김종국 | 프로스타글란딘 e1을 포함하는 온도감응성 에멀젼 외용제조성물 |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
US20050124699A1 (en) * | 2002-07-02 | 2005-06-09 | Wakamoto Pharmaceutical Co., Ltd. | Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells |
KR101027454B1 (ko) | 2002-08-23 | 2011-04-06 | 산텐 세이야꾸 가부시키가이샤 | 라타노프로스트를 유효 성분으로 하는 안정한 점안액 |
CA2707067C (en) | 2002-09-09 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Clear ophthalmic solution comprising latanoprost as active ingredient |
US20040115234A1 (en) * | 2002-09-24 | 2004-06-17 | Gewirtz Joan T. | Cosmetic composition |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP4361294B2 (ja) * | 2003-02-25 | 2009-11-11 | ロート製薬株式会社 | ケトチフェン含有組成物 |
JP4694773B2 (ja) * | 2003-06-06 | 2011-06-08 | ロート製薬株式会社 | 粘膜適用液状組成物 |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
JP5382972B2 (ja) * | 2003-12-26 | 2014-01-08 | ロート製薬株式会社 | 粘度低下が防止された組成物 |
US20050175651A1 (en) * | 2004-01-09 | 2005-08-11 | L'oreal | Aqueous dispersion of nanocapsules with an oily core |
ATE439123T1 (de) | 2004-07-02 | 2009-08-15 | Novagali Pharma Sa | Verwendung von emulsionen zur intra- und periocularen injection |
JP4999304B2 (ja) * | 2004-09-27 | 2012-08-15 | ロート製薬株式会社 | ヒアルロン酸又はその塩を含有する粘膜適用組成物 |
AU2005304035B2 (en) * | 2004-11-09 | 2010-07-22 | Santen Sas | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
ES2314354T3 (es) * | 2004-11-09 | 2009-03-16 | Novagali Pharma S.A. | Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo. |
US20090169629A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Micellar compositions with ophthalmic applications |
US20090170944A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Ophthalmic micellar compositions with enhanced stability |
AU2009260572B2 (en) * | 2008-05-28 | 2015-07-23 | Alcon Research, Ltd. | Self-preserved emulsions |
EP2228058A1 (de) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür |
EP2228057A1 (de) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür |
EP2389939A1 (de) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen |
-
2004
- 2004-11-09 ES ES04292645T patent/ES2314354T3/es active Active
- 2004-11-09 EP EP04292645A patent/EP1655021B1/de active Active
- 2004-11-09 AT AT04292645T patent/ATE412400T1/de not_active IP Right Cessation
- 2004-11-09 DE DE602004017477T patent/DE602004017477D1/de active Active
- 2004-11-18 US US10/991,346 patent/US8298568B2/en active Active
-
2005
- 2005-10-10 NZ NZ554929A patent/NZ554929A/en unknown
- 2005-10-10 AT AT08102553T patent/ATE498392T1/de not_active IP Right Cessation
- 2005-10-10 PT PT05795930T patent/PT1809237E/pt unknown
- 2005-10-10 DK DK05795930T patent/DK1809237T3/da active
- 2005-10-10 CN CNA2005800300698A patent/CN101014317A/zh active Pending
- 2005-10-10 DE DE602005010733T patent/DE602005010733D1/de active Active
- 2005-10-10 PT PT05802097T patent/PT1809238E/pt unknown
- 2005-10-10 AT AT05795930T patent/ATE418964T1/de not_active IP Right Cessation
- 2005-10-10 CN CN2005800383296A patent/CN101056615B/zh active Active
- 2005-10-10 AT AT05802097T patent/ATE412401T1/de not_active IP Right Cessation
- 2005-10-10 MX MX2007003045A patent/MX2007003045A/es active IP Right Grant
- 2005-10-10 AT AT05800012T patent/ATE415942T1/de not_active IP Right Cessation
- 2005-10-10 DE DE602005026464T patent/DE602005026464D1/de active Active
- 2005-10-10 US US11/667,129 patent/US8273362B2/en active Active
- 2005-10-10 ES ES05802097T patent/ES2317319T3/es active Active
- 2005-10-10 US US11/665,066 patent/US8298569B2/en active Active
- 2005-10-10 ZA ZA200703751A patent/ZA200703751B/xx unknown
- 2005-10-10 ES ES05795930T patent/ES2320574T3/es active Active
- 2005-10-10 MX MX2007005545A patent/MX2007005545A/es active IP Right Grant
- 2005-10-10 DE DE602005012136T patent/DE602005012136D1/de active Active
- 2005-10-10 US US11/667,355 patent/US8372434B2/en active Active
- 2005-10-10 DE DE602005011480T patent/DE602005011480D1/de active Active
- 2005-10-10 CN CN201310241506.7A patent/CN103356481B/zh active Active
- 2005-10-10 ES ES05800012T patent/ES2319129T3/es active Active
-
2006
- 2006-10-10 US US12/089,609 patent/US20080268020A1/en not_active Abandoned
-
2007
- 2007-02-20 IL IL181446A patent/IL181446A/en active IP Right Grant
- 2007-05-01 IL IL182897A patent/IL182897A/en unknown
-
2008
- 2008-01-21 HK HK08100777.1A patent/HK1107938A1/xx unknown
- 2008-03-27 IL IL190497A patent/IL190497A/en active IP Right Grant
- 2008-06-17 HK HK08106646.7A patent/HK1112411A1/xx unknown
-
2012
- 2012-04-05 JP JP2012086806A patent/JP5587936B2/ja active Active
- 2012-05-15 JP JP2012111941A patent/JP5773941B2/ja active Active
-
2014
- 2014-02-19 JP JP2014029816A patent/JP5894202B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE412400T1 (de) | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential | |
EA200600877A1 (ru) | Наночастицы для доставки лекарств | |
WO2008013785A3 (en) | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening | |
BRPI0411306A (pt) | composições farmacêuticas compreendendo compostos ativos de vitamina d | |
WO2006108405A3 (de) | Nanopartikel-wirkstoff-konjugate | |
BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
WO2008070538A3 (en) | Micellar nanoparticles comprising botulinum toxin | |
BRPI0906866A2 (pt) | métodos e composições para administração oral de agentes terapêutico de proteína e peptídeo | |
TW200613004A (en) | External preparation of solid/oil type | |
EP2481409A3 (de) | Nanopartikel mit Rapamycin und Albumin als Antikrebsmittel | |
DK1429731T3 (da) | Nanopartikelformuleringer indeholdende insulin | |
BRPI0507680A (pt) | partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas | |
WO2006050837A3 (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
TW200744677A (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
BRPI0607549A2 (pt) | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos | |
EP2301531A3 (de) | Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie | |
ATE422880T1 (de) | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen | |
WO2008085556A3 (en) | Surfactant-free nanoparticles for drug delivery | |
ATE507818T1 (de) | Orale verabreichung eines calcitonins | |
WO2008048205A3 (en) | Method for delivering hydrophobic drugs via nanocrystal formulations | |
ATE508740T1 (de) | Mittel zur verringerung von müdigkeit | |
DE60310605D1 (de) | Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung | |
Sousa et al. | Smart delivery systems for microbial biofilm therapy: dissecting design, drug release and toxicological features | |
ATE341343T1 (de) | Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel | |
CY1109541T1 (el) | Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |